14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RAPT vs TWST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus TWST at $105.61 (N/M Forward P/E, -31.9% operating margin).
Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs TWST. Trailing 12-month operating profitability (RAPT 0.0% vs TWST -31.9%) and valuation multiples (RAPT N/M vs TWST N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment83.9% of Rev ($362M)
90D Engineering Disclosures0 Published · Spatial Genomics
Investor FAQ RAPT vs TWST Key Questions & Quantitative Answers
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus TWST at $105.61 (N/M Forward P/E, -31.9% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
TWST leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus $432M for TWST. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.
TWST screens cheaper on headline valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus TWST (-29.6% ROE) capital efficiency.
In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.